샘플 요청 목록

 카트 문의
시장보고서
상품코드
1785842

세계의 바이오마커 탐색 아웃소싱 서비스 시장

Biomarker Discovery Outsourcing Services
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 216 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 바이오마커 탐색 아웃소싱 서비스 시장은 2030년까지 519억 달러에 이를 전망

2024년에 165억 달러로 추정되는 바이오마커 탐색 아웃소싱 서비스 세계 시장은 2024-2030년 분석 기간에 CAGR 21.0%로 성장하여 2030년에는 519억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 사로 게이트 엔드포인트는 CAGR 22.2%를 나타내고, 분석 기간 종료까지 228억 달러에 이를 것으로 예측됩니다. 예측 바이오마커 분야의 성장률은 분석 기간 CAGR로 19.6%로 추정됩니다.

미국 시장은 43억 달러로 추정, 중국은 CAGR19.9%로 성장 예측

미국의 바이오마커 탐색 아웃소싱 서비스 시장은 2024년에 43억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 79억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 19.9%로 추정됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 19.4%와 18.0%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 약 14.3%를 보일 전망입니다.

세계의 바이오마커 탐색 아웃소싱 서비스 시장 - 주요 동향과 촉진요인 정리

바이오마커 탐색 아웃소싱이 의약품 개발에 있어 중요한 전략이 되고 있는 이유는 무엇일까?

바이오마커 탐색은 제약 및 생명공학 기업들이 약효를 높이고, 환자 선택권을 개선하고, 규제 당국의 승인을 앞당길 수 있도록 하는 현대 의약품 개발에서 매우 중요한 요소로 자리 잡았습니다. 바이오마커 조사의 복잡성과 비용이 증가함에 따라, 많은 기업들이 업무 간소화, 재정적 부담 감소, 전문 지식 활용을 위해 아웃소싱 파트너에게 눈을 돌리고 있습니다. 임상시험수탁기관(CRO) 및 바이오마커 탐색 전문업체는 표적 발굴, 검증, 생물정보학 분석, 약사법 지원 등 엔드투엔드 서비스를 제공함으로써 제약사가 핵심 연구 및 상업화 전략에 집중할 수 있도록 지원합니다. 정밀의료와 동반진단에 대한 수요가 급증하면서 바이오마커 탐색 아웃소싱의 필요성이 더욱 커지고 있습니다. 치료 효과를 예측하기 위해 바이오마커에 대한 의존도가 높아짐에 따라, 아웃소싱 파트너는 바이오마커 분석의 개발 및 검증에 있어 중요한 지원을 제공합니다. 또한, 암, 심혈관질환, 자가면역질환 등 만성질환 증가로 혁신적인 바이오마커의 필요성이 높아지면서 제약사들은 최첨단 기술 및 규제 노하우를 가진 외부 연구기관과 협력하고 있습니다.

기술 발전은 바이오마커 탐색 아웃소싱을 어떻게 변화시킬 것인가?

차세대 염기서열분석(NGS), 단백질체학, 대사체학의 급속한 발전으로 바이오마커 탐색의 상황이 크게 변화하고 있으며, 질병에 특화된 분자 시그니처를 보다 정확하고 효율적으로 식별할 수 있게 되었습니다. 인공지능(AI)과 머신러닝은 데이터 분석에 혁명을 가져왔고, 연구자들은 이전에는 발견할 수 없었던 바이오마커 상관관계를 발견하고 임상시험에서 환자 계층화를 개선할 수 있게 되었습니다. 이러한 첨단 기술은 아웃소싱 서비스 제공업체가 바이오마커의 식별, 검증, 예측 모델링을 강화하여 의약품 개발 일정과 비용을 크게 단축할 수 있도록 돕고 있습니다. 또한, 바이오인포매틱스와 계산생물학의 발전으로 개발업무 위탁기관은 보다 종합적인 바이오마커 탐색 서비스를 제공할 수 있게 되었습니다. 하이스루풋 스크리닝, 단일 세포 분석, 멀티오믹스 접근법은 바이오마커 조사 범위를 확장하고 질병 메커니즘에 대한 보다 정확한 이해를 보장하고 있습니다. 또한, 비침습적 바이오마커 검출을 가능하게 하는 액체생검 기술의 등장은 바이오마커 탐색 아웃소싱 서비스에 침투하여 실시간 질병 모니터링 및 조기 발견을 위한 새로운 길을 제공합니다. 이러한 기술이 계속 발전함에 따라, 바이오마커 기반 의약품 개발을 가속화하고자 하는 제약사들에게 아웃소싱 파트너는 점점 더 필수적인 존재가 되고 있습니다.

바이오마커 탐색 아웃소싱의 성장을 가속하는 시장 동향은?

바이오마커 탐색의 아웃소싱을 촉진하는 가장 중요한 트렌드 중 하나는 맞춤형 의료에 대한 관심이 높아지고 있다는 점입니다. 헬스케어가 맞춤형 치료 전략으로 전환하는 가운데, 제약사들은 아웃소싱 서비스를 활용하여 환자의 정확한 계층화 및 표적 치료를 가능하게 하는 바이오마커를 개발하고 있습니다. 이러한 추세는 특히 암 분야에서 두드러지게 나타나고 있으며, 면역요법 및 표적 암 치료에서 바이오마커 기반 의약품 개발이 매우 중요한 역할을 하고 있습니다. 또 다른 큰 흐름은 신약개발의 타임라인을 앞당기기 위해 제약회사와 CRO(임상시험수탁기관)와의 협력이 진행되고 있다는 점입니다. 바이오마커 탐색 아웃소싱을 통해 제약사는 대규모 내부 투자 없이도 최첨단 기술과 전문성을 활용할 수 있습니다. 또한, FDA, EMA 등 규제 당국이 바이오마커 중심의 의약품 승인을 강조하고 있는 점도 제약사들이 바이오마커 검증 및 컴플라이언스 지원을 아웃소싱하는 동기가 되고 있습니다. 분산형 임상시험과 가상 임상시험의 등장, 원격 바이오마커 수집과 AI를 활용한 데이터 분석이 확산되면서 바이오마커 탐색의 판도를 바꾸고 있습니다.

바이오마커 탐색 아웃소싱 시장의 주요 성장 촉진요인은?

바이오마커 탐색 아웃소싱 서비스 시장의 성장은 바이오마커 연구의 복잡성 증가, 정밀의료에 대한 수요 증가, AI를 활용한 데이터 분석의 발전 등 몇 가지 요인에 의해 이루어지고 있습니다. 자체적으로 바이오마커를 발굴하는 데 드는 비용이 높기 때문에 제약사들은 비용 효율적이고 효율적인 바이오마커 솔루션을 제공할 수 있는 외부 파트너를 찾고 있습니다. 또한, 아웃소싱을 통해 의약품 개발 기업이 다양한 환자군을 대상으로 임상시험을 수행할 수 있게 됨에 따라 임상시험의 세계화와 다지역 바이오마커 검증 시험의 필요성도 시장 개척에 기여하고 있습니다. 또한, 빅데이터 분석과 클라우드 기반 플랫폼의 통합은 바이오마커 탐색의 워크플로우를 간소화하고, 데이터 분석을 개선하며, 임상시험의 성공률을 향상시키고 있습니다. 바이오마커 기반 치료제에 대한 수요가 지속적으로 증가함에 따라, 아웃소싱은 의약품 개발을 가속화하고 개인 맞춤형 의료를 추진하는 데 있어 점점 더 중요한 역할을 할 것으로 예측됩니다.

부문

유형(대체 엔드포인트, 예측 바이오마커, 예후 바이오마커, 안전성 바이오마커), 탐색 단계(바이오마커 식별 단계, 바이오마커 검증 단계, 바이오마커 프로파일링 단계, 바이오마커 패널 개발 단계, 바이오마커 선택 단계), 치료 영역(암치료 영역, 순환기 치료 영역, 신경 치료 영역, 자가면역질환 치료 영역, 기타 치료 영역), 최종사용자(바이오테크놀러지 기업 최종사용자, 제약 기업 최종사용자, 기타 최종사용자)

조사 대상 기업 예

  • AB Sciex LLC
  • BioIVT LLC
  • Charles River Laboratories, Inc.
  • Creative Biolabs
  • Crown Bioscience Inc.
  • Discovery Life Sciences
  • Eurofins Scientific SE
  • Evotec SE
  • Laboratory Corporation of America Holdings
  • Metabolon, Inc.
  • REPROCELL Inc.
  • Sino Biological, Inc.
  • Thermo Fisher Scientific, Inc.

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 일반적인 LLM나 업계별 SLM 쿼리에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

LSH 25.08.14

Global Biomarker Discovery Outsourcing Services Market to Reach US$51.9 Billion by 2030

The global market for Biomarker Discovery Outsourcing Services estimated at US$16.5 Billion in the year 2024, is expected to reach US$51.9 Billion by 2030, growing at a CAGR of 21.0% over the analysis period 2024-2030. Surrogate Endpoints, one of the segments analyzed in the report, is expected to record a 22.2% CAGR and reach US$22.8 Billion by the end of the analysis period. Growth in the Predictive Biomarkers segment is estimated at 19.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.3 Billion While China is Forecast to Grow at 19.9% CAGR

The Biomarker Discovery Outsourcing Services market in the U.S. is estimated at US$4.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$7.9 Billion by the year 2030 trailing a CAGR of 19.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 19.4% and 18.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.3% CAGR.

Global Biomarker Discovery Outsourcing Services Market - Key Trends & Drivers Summarized

Why Is Biomarker Discovery Outsourcing Becoming a Critical Strategy for Drug Development?

Biomarker discovery has become a crucial element in modern drug development, enabling pharmaceutical and biotech companies to enhance drug efficacy, improve patient selection, and accelerate regulatory approvals. Given the growing complexity and cost of biomarker research, many companies are turning to outsourcing partners to streamline operations, reduce financial burdens, and leverage specialized expertise. Contract research organizations (CROs) and specialized biomarker discovery firms offer end-to-end services, including target identification, validation, bioinformatics analysis, and regulatory support, allowing pharmaceutical firms to focus on core research and commercialization strategies. The surge in demand for precision medicine and companion diagnostics has further fueled the need for biomarker discovery outsourcing. As drug developers increasingly rely on biomarkers to predict therapeutic responses, outsourcing partners are providing critical support in biomarker assay development and validation. Additionally, the rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and autoimmune conditions has intensified the need for innovative biomarkers, prompting pharmaceutical companies to collaborate with external research organizations that have cutting-edge technologies and regulatory know-how.

How Are Technological Advancements Transforming Biomarker Discovery Outsourcing?

The rapid evolution of next-generation sequencing (NGS), proteomics, and metabolomics is reshaping the biomarker discovery landscape, enabling more precise and efficient identification of disease-specific molecular signatures. Artificial intelligence (AI) and machine learning are revolutionizing data analysis, allowing researchers to uncover previously undetectable biomarker correlations and improve patient stratification in clinical trials. These advanced technologies are helping outsourcing service providers enhance biomarker identification, validation, and predictive modeling, significantly reducing drug development timelines and costs. Furthermore, advances in bioinformatics and computational biology are enabling contract research organizations to provide more comprehensive biomarker discovery services. High-throughput screening, single-cell analysis, and multi-omics approaches are expanding the scope of biomarker research, ensuring a more accurate understanding of disease mechanisms. Additionally, the rise of liquid biopsy techniques, which allow for non-invasive biomarker detection, is gaining traction in outsourced biomarker discovery services, offering new avenues for real-time disease monitoring and early detection. As these technologies continue to evolve, outsourcing partners are becoming increasingly indispensable for pharmaceutical companies seeking to accelerate biomarker-driven drug development.

What Market Trends Are Driving the Growth of Biomarker Discovery Outsourcing?

One of the most significant trends driving biomarker discovery outsourcing is the growing emphasis on personalized medicine. As healthcare shifts toward tailored treatment strategies, pharmaceutical firms are leveraging outsourcing services to develop biomarkers that enable precise patient stratification and targeted therapies. This trend is particularly evident in oncology, where biomarker-driven drug development is playing a pivotal role in immunotherapy and targeted cancer treatments. Another major trend is the increasing collaboration between pharmaceutical companies and contract research organizations to accelerate drug discovery timelines. Outsourcing biomarker discovery allows drug developers to access cutting-edge technologies and specialized expertise without the need for extensive in-house investments. Additionally, regulatory agencies such as the FDA and EMA are placing greater emphasis on biomarker-driven drug approvals, incentivizing pharmaceutical firms to outsource biomarker validation and compliance support. The rise of decentralized and virtual clinical trials is also reshaping the biomarker discovery landscape, as remote biomarker collection and AI-powered data analysis gain traction.

What Are the Key Growth Drivers for the Biomarker Discovery Outsourcing Market?

The growth in the Biomarker Discovery Outsourcing Services market is driven by several factors including the increasing complexity of biomarker research, rising demand for precision medicine, and advancements in AI-driven data analytics. The high costs associated with in-house biomarker discovery are prompting pharmaceutical companies to seek external partners that can provide cost-effective and efficient biomarker solutions. The globalization of clinical trials and the need for multi-regional biomarker validation studies are also contributing to market expansion, as outsourcing enables drug developers to conduct studies across diverse patient populations. Additionally, the integration of big data analytics and cloud-based platforms is streamlining biomarker discovery workflows, improving data interpretation, and enhancing clinical trial success rates. As the demand for biomarker-driven therapeutics continues to grow, outsourcing is expected to play an increasingly pivotal role in accelerating drug development and advancing personalized medicine.

SCOPE OF STUDY:

The report analyzes the Biomarker Discovery Outsourcing Services market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers); Discovery Phase (Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase, Biomarker Selection Phase); Therapeutic Area (Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area, Other Therapeutic Areas); End-Use (Biotechnology Companies End-Use, Pharmaceutical Companies End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

  • AB Sciex LLC
  • BioIVT LLC
  • Charles River Laboratories, Inc.
  • Creative Biolabs
  • Crown Bioscience Inc.
  • Discovery Life Sciences
  • Eurofins Scientific SE
  • Evotec SE
  • Laboratory Corporation of America Holdings
  • Metabolon, Inc.
  • REPROCELL Inc.
  • Sino Biological, Inc.
  • Thermo Fisher Scientific, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Biomarker Discovery Outsourcing Services - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increased Complexity of Early Drug Discovery Pipelines Throws the Spotlight on Outsourced Biomarker Discovery Services
    • Expansion of Multi-Omics Platforms Drives Demand for Integrated Discovery and Validation Capabilities
    • Rising Use of AI in Biomarker Pattern Recognition Spurs Adoption of Advanced Computational Discovery Models
    • OEM Preference for Targeted and Predictive Biomarkers Strengthens Value Proposition of External Discovery Experts
    • Growth in Stratified Medicine and Early Disease Detection Fuels Need for Rapid Biomarker Identification Workflows
    • Integration of Mass Spectrometry, NGS, and Proteomics Enhances Analytical Sophistication in Discovery Outsourcing
    • Use of Patient-Derived Organoids and Cell Lines Expands Biological Relevance in Biomarker Screening
    • Rising Investment in Biomarker Discovery for Neurodegenerative and Autoimmune Diseases Spurs Outsourced R&D
    • Development of Microbiome and Metabolome Biomarkers Broadens Scope of Discovery Services
    • OEM Collaboration With Biobanks and Data Lakes Strengthens Sample Access for Exploratory Biomarker Projects
    • Emergence of Digital Biomarkers and Sensor-Based Platforms Drives Demand for Cross-Functional Discovery Teams
    • Growth in Oncology Pipeline Assets Promotes Early Identification of Prognostic and Predictive Biomarkers
    • OEM Interest in Preclinical Biomarker Panels and Translational Research Accelerates CRO Engagement
    • Increased Emphasis on Early-Stage Regulatory Consultation Promotes Use of Validated Discovery Frameworks
    • Expansion of Biomarker IP Portfolios Encourages Outsourcing of Discovery With Tech Transfer Rights
    • Rising Use of Multi-Site and Cross-Population Biomarker Validation Strengthens Role of Global Discovery CROs
    • OEM Demand for Biomarker Qualification and Assay Transferability Fuels Service Model Integration
    • Emergence of High-Throughput Single-Cell Technologies Spurs Innovation in Functional Biomarker Screening
    • Cost and Timeline Pressure in Drug Discovery Enhances Outsourcing of Specialized Biomarker Tasks
    • Academic and Biotech Alliances With CROs Promote Public-Private Biomarker Discovery Ecosystems
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Biomarker Discovery Outsourcing Services Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Biomarker Discovery Outsourcing Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Surrogate Endpoints by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Surrogate Endpoints by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Predictive Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Predictive Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Prognostic Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Prognostic Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Safety Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Safety Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Oncology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Oncology Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Cardiology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Cardiology Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Neurology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Neurology Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Autoimmune Diseases Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Autoimmune Diseases Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Biotechnology Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Biotechnology Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Pharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Biomarker Identification Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for Biomarker Identification Phase by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 30: World Recent Past, Current & Future Analysis for Biomarker Validation Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 31: World 6-Year Perspective for Biomarker Validation Phase by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Biomarker Profiling Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World 6-Year Perspective for Biomarker Profiling Phase by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Biomarker Panel Development Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 35: World 6-Year Perspective for Biomarker Panel Development Phase by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 36: World Recent Past, Current & Future Analysis for Biomarker Selection Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 37: World 6-Year Perspective for Biomarker Selection Phase by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Biomarker Discovery Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Type - Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA 6-Year Perspective for Biomarker Discovery Outsourcing Services by Type - Percentage Breakdown of Value Sales for Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers for the Years 2025 & 2030
    • TABLE 40: USA Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: USA 6-Year Perspective for Biomarker Discovery Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 42: USA Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: USA 6-Year Perspective for Biomarker Discovery Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Discovery Phase - Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA 6-Year Perspective for Biomarker Discovery Outsourcing Services by Discovery Phase - Percentage Breakdown of Value Sales for Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase for the Years 2025 & 2030
  • CANADA
    • TABLE 46: Canada Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Type - Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Canada 6-Year Perspective for Biomarker Discovery Outsourcing Services by Type - Percentage Breakdown of Value Sales for Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers for the Years 2025 & 2030
    • TABLE 48: Canada Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Canada 6-Year Perspective for Biomarker Discovery Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada 6-Year Perspective for Biomarker Discovery Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 52: Canada Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Discovery Phase - Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Canada 6-Year Perspective for Biomarker Discovery Outsourcing Services by Discovery Phase - Percentage Breakdown of Value Sales for Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase for the Years 2025 & 2030
  • JAPAN
    • Biomarker Discovery Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 54: Japan Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Type - Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Japan 6-Year Perspective for Biomarker Discovery Outsourcing Services by Type - Percentage Breakdown of Value Sales for Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers for the Years 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan 6-Year Perspective for Biomarker Discovery Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 58: Japan Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Japan 6-Year Perspective for Biomarker Discovery Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 60: Japan Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Discovery Phase - Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Japan 6-Year Perspective for Biomarker Discovery Outsourcing Services by Discovery Phase - Percentage Breakdown of Value Sales for Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase for the Years 2025 & 2030
  • CHINA
    • Biomarker Discovery Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Type - Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China 6-Year Perspective for Biomarker Discovery Outsourcing Services by Type - Percentage Breakdown of Value Sales for Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers for the Years 2025 & 2030
    • TABLE 64: China Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: China 6-Year Perspective for Biomarker Discovery Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 66: China Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: China 6-Year Perspective for Biomarker Discovery Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Discovery Phase - Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China 6-Year Perspective for Biomarker Discovery Outsourcing Services by Discovery Phase - Percentage Breakdown of Value Sales for Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase for the Years 2025 & 2030
  • EUROPE
    • Biomarker Discovery Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 70: Europe Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 71: Europe 6-Year Perspective for Biomarker Discovery Outsourcing Services by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 72: Europe Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Type - Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Europe 6-Year Perspective for Biomarker Discovery Outsourcing Services by Type - Percentage Breakdown of Value Sales for Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers for the Years 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe 6-Year Perspective for Biomarker Discovery Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 76: Europe Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Europe 6-Year Perspective for Biomarker Discovery Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 78: Europe Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Discovery Phase - Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Europe 6-Year Perspective for Biomarker Discovery Outsourcing Services by Discovery Phase - Percentage Breakdown of Value Sales for Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase for the Years 2025 & 2030
  • FRANCE
    • Biomarker Discovery Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Type - Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France 6-Year Perspective for Biomarker Discovery Outsourcing Services by Type - Percentage Breakdown of Value Sales for Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers for the Years 2025 & 2030
    • TABLE 82: France Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: France 6-Year Perspective for Biomarker Discovery Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 84: France Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: France 6-Year Perspective for Biomarker Discovery Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Discovery Phase - Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France 6-Year Perspective for Biomarker Discovery Outsourcing Services by Discovery Phase - Percentage Breakdown of Value Sales for Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase for the Years 2025 & 2030
  • GERMANY
    • Biomarker Discovery Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 88: Germany Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Type - Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Germany 6-Year Perspective for Biomarker Discovery Outsourcing Services by Type - Percentage Breakdown of Value Sales for Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers for the Years 2025 & 2030
    • TABLE 90: Germany Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Germany 6-Year Perspective for Biomarker Discovery Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany 6-Year Perspective for Biomarker Discovery Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 94: Germany Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Discovery Phase - Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Germany 6-Year Perspective for Biomarker Discovery Outsourcing Services by Discovery Phase - Percentage Breakdown of Value Sales for Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase for the Years 2025 & 2030
  • ITALY
    • TABLE 96: Italy Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Type - Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Italy 6-Year Perspective for Biomarker Discovery Outsourcing Services by Type - Percentage Breakdown of Value Sales for Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers for the Years 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy 6-Year Perspective for Biomarker Discovery Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 100: Italy Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Italy 6-Year Perspective for Biomarker Discovery Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 102: Italy Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Discovery Phase - Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Italy 6-Year Perspective for Biomarker Discovery Outsourcing Services by Discovery Phase - Percentage Breakdown of Value Sales for Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase for the Years 2025 & 2030
  • UNITED KINGDOM
    • Biomarker Discovery Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Type - Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK 6-Year Perspective for Biomarker Discovery Outsourcing Services by Type - Percentage Breakdown of Value Sales for Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers for the Years 2025 & 2030
    • TABLE 106: UK Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: UK 6-Year Perspective for Biomarker Discovery Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 108: UK Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 109: UK 6-Year Perspective for Biomarker Discovery Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Discovery Phase - Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK 6-Year Perspective for Biomarker Discovery Outsourcing Services by Discovery Phase - Percentage Breakdown of Value Sales for Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 112: Rest of Europe Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Type - Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Rest of Europe 6-Year Perspective for Biomarker Discovery Outsourcing Services by Type - Percentage Breakdown of Value Sales for Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers for the Years 2025 & 2030
    • TABLE 114: Rest of Europe Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 115: Rest of Europe 6-Year Perspective for Biomarker Discovery Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of Europe 6-Year Perspective for Biomarker Discovery Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 118: Rest of Europe Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Discovery Phase - Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Rest of Europe 6-Year Perspective for Biomarker Discovery Outsourcing Services by Discovery Phase - Percentage Breakdown of Value Sales for Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Biomarker Discovery Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 120: Asia-Pacific Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Type - Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Asia-Pacific 6-Year Perspective for Biomarker Discovery Outsourcing Services by Type - Percentage Breakdown of Value Sales for Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers for the Years 2025 & 2030
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific 6-Year Perspective for Biomarker Discovery Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 124: Asia-Pacific Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Asia-Pacific 6-Year Perspective for Biomarker Discovery Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 126: Asia-Pacific Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Discovery Phase - Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 127: Asia-Pacific 6-Year Perspective for Biomarker Discovery Outsourcing Services by Discovery Phase - Percentage Breakdown of Value Sales for Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 128: Rest of World Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Type - Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of World 6-Year Perspective for Biomarker Discovery Outsourcing Services by Type - Percentage Breakdown of Value Sales for Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers for the Years 2025 & 2030
    • TABLE 130: Rest of World Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 131: Rest of World 6-Year Perspective for Biomarker Discovery Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 132: Rest of World Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 133: Rest of World 6-Year Perspective for Biomarker Discovery Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Discovery Phase - Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of World 6-Year Perspective for Biomarker Discovery Outsourcing Services by Discovery Phase - Percentage Breakdown of Value Sales for Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase for the Years 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제